MVZ Gastro Berlin
- Address
- Innsbrucker Straße 58, 10825 Berlin, Germany
Digestive System Diseases
At MVZ Gastro Berlin, the clinical trial portfolio in gastroenterology focuses on inflammatory bowel disease and related digestive conditions. Research is centered on Crohn's disease and ulcerative colitis, with studies designed to assess new treatment options and long-term disease control.
- Evaluating the safety and effectiveness of new therapies for moderately to severely active ulcerative colitis
- Studying combination approaches for Crohn's disease and ulcerative colitis
- Exploring maintenance strategies to support lasting symptom control in inflammatory bowel disease
These trials aim to improve how chronic intestinal inflammation is managed, with a strong emphasis on better disease control, sustained response, and overall treatment effectiveness.
Immune System Diseases
The site also contributes to research in immune-mediated diseases, especially conditions where the body's immune response affects the liver and digestive tract. A key focus is primary biliary cholangitis, alongside immune-related forms of ulcerative colitis.
- Testing a new therapy for primary biliary cholangitis in patients with limited response to standard care
- Assessing whether treatment can improve cholestasis and liver-related outcomes
- Examining the long-term safety and benefit of immune-targeted treatments in autoimmune disease
At Gastroenterologie am Bayerischen Platz, this research supports efforts to find more effective options for patients with difficult-to-treat immune and liver conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ Gastro Berlin
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Elafibranor in Primary Biliary Cholangitis Patients with Inadequate Ursodeoxycholic Acid Response: A Double-Blind, Placebo-Controlled Study | Ipsen Pharma | Phase IV | Not Recruiting | Jan 2021 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Golimumab | 2 | Unknown | 2022-11-30 | 2022-11-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.